CN104548106A - Bioactive hyaluronic acid syrup preparation - Google Patents
Bioactive hyaluronic acid syrup preparation Download PDFInfo
- Publication number
- CN104548106A CN104548106A CN201510065498.4A CN201510065498A CN104548106A CN 104548106 A CN104548106 A CN 104548106A CN 201510065498 A CN201510065498 A CN 201510065498A CN 104548106 A CN104548106 A CN 104548106A
- Authority
- CN
- China
- Prior art keywords
- hyaluronic acid
- biological activity
- syrup preparation
- sorbitol
- activity hyaluronic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a bioactive hyaluronic acid syrup preparation, which comprises bioactive hyaluronic acid with anti-inflammatory activity, and sorbitol having synergistic effect together with the bioactive hyaluronic acid. The syrup preparation can promote the health of mouth and throat mucosa, and treat syndromes such as cough and the like caused by throat inflammation.
Description
Technical field
The present invention relates to a kind of biological activity hyaluronic acid syrup preparation.
Background technology
Laryngopharynx disease has long, the easy feature repeatedly of the course of disease more, a lot of patient's long-term existence itching throat, foreign body sensation, hawk, numerous pharyngeal symptom such as throat burn feeling, in recent years, along with going deep into of research, find that many laryngopharynx disorder all have substantial connection with gastric content from backwards flowing to bottleneck throat, within 2002, this noun of laryngopharynx reflux disease is formally adopted by ENT & HN Surgery Dept. association of the U.S..The cause of disease of many patients may be laryngopharynx reflux disease, does not also have effective Therapeutic Method at present for this disease, and patient's prolonged application has pharyngitis medicine all poor effect.
Research external recently shows, extracellular matrix macromole hyaluronic acid is become biological activity hyaluronic acid by hyaluronic acid enzyme activation, biological activity hyaluronic acid and extracellular CD44 and TLR4 receptors bind, can promote the inflammatory stimulus effect of mucocutaneous secretion defensin 2, inflammation-inhibiting and anti-endotoxin.Therefore, development one biological activity hyaluronic acid safely and effectively, makes syrup preparation for oral administration, and can expect provides a kind of approach promoting oropharynx larynx mucosal health, alleviate abnormal pharyngeal symptom, treat laryngopharyngitis.
Summary of the invention
The object of this invention is to provide a kind of biological activity hyaluronic acid syrup preparation, make it have efficient anti-inflammatory activity, effectively can promote oropharynx larynx mucosal health and treat mouth, pharynx, larynx, esophageal inflammation, the pharyngeal discomfort that the malaise symptoms of alleviation control pars oralis pharyngis, especially laryngopharynx reflux disease cause.
For achieving the above object, the present invention adopts following technical scheme:
A kind of biological activity hyaluronic acid syrup preparation, comprises the biological activity hyaluronic acid with anti-inflammatory activity, has the synergistic Sorbitol of potentiation with described biological activity hyaluronic acid.
Further, the biological activity hyaluronic acid fragments of to be molecular weight the be 0.7KD-100KD of the biological activity hyaluronic acid described in anti-inflammatory activity.
Further, described biological activity hyaluronic acid fragments is that the recombined human hyaluronidase PH20 of saccharifying that has using Chinese hamster ovary celI to produce cuts the acquisition of macromole hyaluronic acid, and described hyaluronic acid fragments has at least one end to be the end using the recombined human hyaluronidase cutting that can identify hyaluronic acid normal configuration.
Further, described syrup preparation is low sugar syrup preparation, comprise the following component of percentage by weight: described biological activity hyaluronic acid 6-12%, Sorbitol 30-50%, white sugar 0.1-1%, brown sugar 0.5-2%, maltose alcohol 0.5-6.7%, Mel 0.1-1%, sodium benzoate 0.1-0.3%, Mint Essence 0.001-0.01%, surplus is water.
Further, described low sugar syrup preparation comprises the following component of percentage by weight: described biological activity hyaluronic acid 10%, Sorbitol 40%, white sugar 1%, brown sugar 2%, maltose alcohol 6.7%, Mel 1%, sodium benzoate 0.3%, Mint Essence 0.01%, and surplus is water.
Further, described syrup preparation is high sugared syrup preparation, comprise the following component of percentage by weight: described biological activity hyaluronic acid 6-12%, Sorbitol 1-3%, maltose 30-35%, sucrose 10-12%, brown sugar 10%, Mel 1-3%, Mint Essence 0.5-1%, surplus is water.
Further, the sugared syrup preparation of described height comprises the following component of percentage by weight: described biological activity hyaluronic acid 10%, Sorbitol 2%, maltose 30%, sucrose 10%, brown sugar 10%, Mel 3%, Mint Essence 1%, and surplus is water.
Owing to adopting technique scheme, the present invention at least has the following advantages:
Biological activity hyaluronic acid syrup preparation of the present invention can promote oropharynx larynx mucosal health and treatment mouth, pharynx, larynx, esophageal inflammation, alleviates and controls the malaise symptoms that causes of these inflammation, especially the pharyngeal discomfort that causes of laryngopharynx reflux disease.
The adjuvant Sorbitol adopted in the present invention and biological activity hyaluronic acid have synergistic function, can increase the hyaluronic biological activity of biological activity and human body therapy effect.
Detailed description of the invention
The present invention is intended to utilize biological activity hyaluronic acid safely and effectively, and is made into edible syrup preparation, as health food or medical usage.In view of the hyaluronic specific use of biological activity, need to develop the suitable syrup adjuvant of compatibility.
Foodstuff glue is that a class can improve food viscosity or form the food additive of gel, is the food additive having a class of extensive use important in the food industry.Foodstuff glue generally has some characteristics like this: in water, have certain solubility; Strongly swelling in water, can dissolve rapidly or gelatinizing in certain temperature range; Aqueous solution has larger viscosity, in most of the cases has the character of non-Newtonian fluid; Part foodstuff glue can form gel and thin film under certain condition.
By a large amount of experimentation multiple auxiliary materials, inventor finds, if xanthan gum, modified guar, carrageenan, pectin, gelatin, plain meat powder, agar, starch (also comprising collagen protein, soybean protein hydrolyate, yeast proteolytic thing) are as the poor effect of adjuvant.Some adjuvant not only can not increase the hyaluronic biologically active human of biological activity, even can reduce the hyaluronic biologically active human of biological activity, suppresses result of use.
But inventor is surprised to find, Sorbitol does not only reduce the hyaluronic biological activity of biological activity, facilitates the hyaluronic human body result of use of biological activity on the contrary, has the hyaluronic synergism with biological activity.This synergism enhances the hyaluronic antiphlogistic effects of biological activity, and therefore, Sorbitol is as being also a kind of synergetic effect additive while syrup adjuvant.
The present invention utilizes above-mentioned discovery to provide to have the biological activity hyaluronic acid syrup preparation of efficient anti-inflammatory activity, comprises the biological activity hyaluronic acid with anti-inflammatory activity, and has the synergistic Sorbitol of potentiation with described biological activity hyaluronic acid.
The biological activity hyaluronic acid fragments of the described biological activity hyaluronic acid with anti-inflammatory activity to be molecular weight be 0.7KD-100KD.What described biological activity hyaluronic acid fragments can adopt Chinese hamster ovary celI to produce has the hyaluronic mode of the recombined human hyaluronidase PH20 of saccharifying cutting macromole to obtain, and described hyaluronic acid fragments has at least one end to be the end using the recombined human hyaluronidase cutting that can identify hyaluronic acid normal configuration.The biological activity hyaluronic acid adopting which to obtain has the advantages that safety is high, biological activity is high.
In order to provide the syrup preparation of applicable different use crowd, through actual effect checking, the invention provides the low sugar syrup preparation of following applicable diabetes patient and adiposis patient use and the height sugar syrup preparation of applicable children taking:
Described low sugar syrup preparation comprises the following component of percentage by weight: described biological activity hyaluronic acid fragments 6-12%, Sorbitol 30-50%, white sugar 0.1-1%, brown sugar 0.5-2%, maltose alcohol 0.5-6.7%, Mel 0.1-1%, sodium benzoate 0.1-0.3%, Mint Essence 0.001-0.01%, surplus is water.
Preferably, described low sugar syrup preparation comprises the following component of percentage by weight: described biological activity hyaluronic acid 10%, Sorbitol 40%, white sugar 1%, brown sugar 2%, maltose alcohol 6.7%, Mel 1%, sodium benzoate 0.3%, Mint Essence 0.01%, and surplus is water.
The sugared syrup preparation of described height comprises the following component of percentage by weight: described biological activity hyaluronic acid fragments 6-12%, Sorbitol 1-3%, maltose 30-35%, sucrose 10-12%, brown sugar 10%, Mel 1-3%, Mint Essence 0.5-1%, surplus is water.
Preferably, the sugared syrup preparation of described height comprises the following component of percentage by weight: described biological activity hyaluronic acid 10%, Sorbitol 2%, maltose 30%, sucrose 10%, brown sugar 10%, Mel 3%, Mint Essence 1%, and surplus is water.
Above-mentioned is only the general introduction of technical solution of the present invention, and in order to better understand technological means of the present invention, below in conjunction with detailed description of the invention, the present invention is described in further detail.
Embodiment 1
Object: the production method of biological activity hyaluronic acid fragments.
Method: raw material is the macromole hyaluronic acid of the 200-600KD of purity 90.0%-99.9%, the recombined human hyaluronidase PH20 using Chinese hamster ovary celI to produce cuts, every gram of hyaluronic acid uses hyaluronidase 1000-2000 unit, 37 degree of digestion 4-6 hour, pH5.0-5.5,130-160mM NaCl, 0.5-1.0mMMgSO
4, 1.5-2.5mM CaCl
2, the molecular weight finally made is 0.7KD-100KD hyaluronic acid fragments.
Described molecular weight be 0.7KD-100KD hyaluronic acid fragments have at least one end be use Chinese hamster ovary celI produce do not cause the mankind anaphylactoid have saccharifying can identify hyaluronic acid normal configuration recombined human hyaluronidase PH20 cut end, have and promote emiocytosis defensin 2, killing microorganisms and the biological activity with the mucocutaneous inflammation of suppression, described biological activity had both depended on the hyaluronic acid fragments end that hyaluronidase cuts, also the molecular size range of hyaluronic acid fragments is depended on, the molecular weight of hyaluronic acid fragments is less, the end that contained recombined human hyaluronidase PH20 cuts is more, biological activity is better.
Embodiment 2
Object: research different sugar slurry formulation adjuvant is on the impact of the hyaluronic biologically active human of biological activity.
Method: this experiment adopts the method for human experimentation to detect the hyaluronic biologically active human of biological activity, namely different high concentration glue unguentum adjuvant is on the impact of biological activity hyaluronic acid treatment laryngopharynx portion Inflammatory effects.
This experiment toy preliminary experiment has in advance found that glue (cream) agent adjuvant xanthan gum, modified guar, carrageenan, pectin, gelatin, plain meat powder, agar, starch (also comprising collagen protein, soybean protein hydrolyate, yeast proteolytic thing) all reduce or do not increase the hyaluronic biologically active human of biological activity.
This is tested all cases and is pharyngolaryngitis patient, experimental group 1 (Sorbitol) adopts Sorbitol 40%+ biological activity hyaluronic acid 10% low sugar syrup buccal every day 6 times, each 3-5ml, the situation of the cough symptom that pharyngolaryngitis Signs and laryngopharyngitis cause after observing treatment; Experimental group 2 (xanthan gum) adopts xanthan gum 40%+ biological activity hyaluronic acid 10% low sugar syrup buccal every day 6 times, each 3-5ml, the situation of the cough symptom that pharyngolaryngitis Signs and laryngopharyngitis cause after observing treatment; Experimental group 3 (starch) adopts starch 40%+ biological activity hyaluronic acid 10% low sugar syrup buccal every day 6 times, each 3-5ml, the situation of the cough symptom that pharyngolaryngitis Signs and laryngopharyngitis cause after observing treatment; Experimental group 4 (yeast proteolytic thing) adopts yeast proteolytic thing 40%+ biological activity hyaluronic acid 10% low sugar syrup buccal every day 6 times, each 3-5ml, the situation of the cough symptom that pharyngolaryngitis Signs and laryngopharyngitis cause after observing treatment; Positive control adopts 10% biological activity hyaluronic acid buccal every day 6 times, each 3-5ml, the situation of the cough symptom that pharyngolaryngitis Signs and laryngopharyngitis cause after observing treatment; Negative control adopts various sugar mixture 40% syrup buccal every day 6 times, each 3-5ml, the situation of the cough symptom that pharyngolaryngitis Signs and laryngopharyngitis cause after observing treatment; Relatively treat sings and symptoms improvement situation after 3 days for six groups.
Cough symptom therapeutic evaluation: effective: symptom is significantly improved or disappeared, patient satisfaction; Effective: symptom is improved or alleviates, and patient still has discomfort, requires continual cure; Invalid: symptom is without obviously alleviating, and patient is unsatisfied with.
Sign therapeutic evaluation: effective: pharyngeal redness obviously shoals; Effective: pharyngeal redness starts to shoal; Invalid: pharyngeal redness does not start to shoal.
Statistical method: adopt SPSS12.0 statistics software to carry out statistical procedures, compare between metering and enumeration data group and adopt t inspection and x
2inspection, with p<0.05 for there being statistical significance difference.
Result:
As shown in table 1, within the 4th day, symptom improves situation: effective 10 examples of experimental group 1, total effective rate 100%; Effective 6 examples of experimental group 2, invalid 4 examples, total effective rate 60%, obvious effective rate compares P<0.01 with experimental group 1; Effective 7 examples of experimental group 3, invalid 3 examples, total effective rate 70%, obvious effective rate compares P<0.01 with experimental group 1; Effective 6 examples of experimental group 4, invalid 4 examples, total effective rate 60%, obvious effective rate compares P<0.01 with experimental group 1.
Table 1 the 4th day each group patients symptomatic improves situation and compares
As shown in table 2, within the 4th day, clinical sign improves situation: effective 10 examples of experimental group 1, total effective rate 100%; Effective 6 examples of experimental group 2, invalid 4 examples, total effective rate 60%, obvious effective rate compares P<0.01 with experimental group 1; Effective 7 examples of experimental group 3, invalid 3 examples, total effective rate 70%, obvious effective rate compares P<0.01 with experimental group 1; Effective 6 examples of experimental group 4, invalid 4 examples, total effective rate 60%, obvious effective rate compares P<0.01 with experimental group 1.
Table 2 is respectively organized patient sign improvement situation on the 4th day and is compared
Conclusion: with human experimentation, experimental group 1 (Sorbitol) obviously than experimental group 2 (xanthan gum), experimental group 3 (starch), experimental group 4 (yeast proteolytic thing) effectively, shows that the curative effect of (1) Sorbitol to biological activity hyaluronic acid treatment pharyngitis and cough has obvious synergism; (2) xanthan gum, starch, the curative effect of yeast proteolytic thing to biological activity hyaluronic acid treatment pharyngitis and cough do not have facilitation.
Embodiment 3
Biological activity hyaluronic acid low sugar syrup
Formula (percentage by weight): biological activity hyaluronic acid 10%, Sorbitol 40%, white sugar 1%, brown sugar 2%, maltose alcohol 6.7%, Mint Essence 0.01%, Mel 1%, sodium benzoate 0.3%, surplus is water.I.e. embodiment 1 experimental group 1 formula.
Embodiment 4
The high syrup of biological activity hyaluronic acid
Formula (percentage by weight): biological activity hyaluronic acid 6-12%, Sorbitol 1-3%, maltose 30-35%, sucrose 10-12%, brown sugar 10%, Mel 1-3%, Mint Essence 0.5-1%, surplus is water.
Preferably, described height syrup comprises biological activity hyaluronic acid 10%, Sorbitol 2%, maltose 30%, sucrose 10%, brown sugar 10%, Mel 3%, Mint Essence 1%, and surplus is water.
Method: preparation 20-25% biological activity hyaluronic acid solution, directly mix, or heating, vacuum dewaters, prepare the 6-12% biological activity hyaluronic acid syrup of above formula with 30% maltose, 10% sucrose, 10% brown sugar, 3% Mel, 1% Mint Essence.This is tested all cases and is pharyngolaryngitis patient, experimental group 1-4 adopts above-mentioned syrup buccal every day 6 times of biological activity hyaluronic acid 6%, 8%, 10%, 12% respectively, each 3-5ml, the situation of the cough symptom that pharyngolaryngitis Signs and laryngopharyngitis cause after observing treatment; Positive control 1-4 adopts 6%, 8%, 10%, 12% biological activity hyaluronic acid buccal every day 6 times respectively, each 3-5ml, the situation of the cough symptom that pharyngolaryngitis Signs and laryngopharyngitis cause after observing treatment; Negative control adopts and does not contain hyaluronic various sugar mixture syrup buccal every day of biological activity 6 times, each 3-5ml, the situation of the cough symptom that pharyngolaryngitis Signs and laryngopharyngitis cause after observing treatment; Often organize 4 patients, compare 12 groups and treat sings and symptoms improvement situation after 3 days.
Cough symptom therapeutic evaluation: effective: symptom is significantly improved or disappeared, patient satisfaction; Effective: symptom is improved or alleviates, and patient still has discomfort, requires continual cure; Invalid: symptom is without obviously alleviating, and patient is unsatisfied with.
Sign therapeutic evaluation: effective: pharyngeal redness obviously shoals; Effective: pharyngeal redness starts to shoal; Invalid: pharyngeal redness does not start to shoal.
Statistical method: adopt SPSS12.0 statistics software to carry out statistical procedures, compare between metering and enumeration data group and adopt t inspection and x
2inspection, with p<0.05 for there being statistical significance difference.
Result: table 3 is respectively organized patient sign improvement situation on the 4th day and compared
Each experimental group group compares above, P>0.05, indifference.
Conclusion: use experiment through human body, result shows that use 6%, 8%, 10%, 12% biological activity hyaluronic acid syrup all has therapeutic effect to laryngopharyngitis.
Embodiment 5
Object: research variable concentrations Sorbitol low sugar syrup adjuvant is on the impact of the hyaluronic biologically active human of biological activity.
Method: manufacture 6%, 8%, 10%, 12% biological activity hyaluronic acid and 30%, 40%, 50% Sorbitol low sugar syrup, suitably the % content of other adjuvant of adjustment.This is tested all cases and is pharyngolaryngitis patient, experimental group 1-4 adopts Sorbitol 30%+ biological activity hyaluronic acid 6%, 8%, 10%, 12% low sugar syrup buccal every day 6 times respectively, each 3-5ml, the situation of the cough symptom that pharyngolaryngitis Signs and laryngopharyngitis cause after observing treatment; Experimental group 5-8 adopts Sorbitol 40%+ biological activity hyaluronic acid 6%, 8%, 10%, 12% low sugar syrup buccal every day 6 times respectively, each 3-5ml, the situation of the cough symptom that pharyngolaryngitis Signs and laryngopharyngitis cause after observing treatment; Experimental group 9-12 adopts Sorbitol 50%+ biological activity hyaluronic acid 6%, 8%, 10%, 12% low sugar syrup buccal every day 6 times respectively, each 3-5ml, the situation of the cough symptom that pharyngolaryngitis Signs and laryngopharyngitis cause after observing treatment; Positive control 1-4 adopts 6%, 8%, 10%, 12% biological activity hyaluronic acid buccal every day 6 times respectively, each 3-5ml, the situation of the cough symptom that pharyngolaryngitis Signs and laryngopharyngitis cause after observing treatment; Negative control adopts and does not contain hyaluronic various sugar mixture syrup buccal every day of biological activity 6 times, each 3-5ml, the situation of the cough symptom that pharyngolaryngitis Signs and laryngopharyngitis cause after observing treatment; Often organize 4 patients, compare 12 groups and treat sings and symptoms improvement situation after 3 days.
Cough symptom therapeutic evaluation: effective: symptom is significantly improved or disappeared, patient satisfaction; Effective: symptom is improved or alleviates, and patient still has discomfort, requires continual cure; Invalid: symptom is without obviously alleviating, and patient is unsatisfied with.
Sign therapeutic evaluation: effective: pharyngeal redness obviously shoals; Effective: pharyngeal redness starts to shoal; Invalid: pharyngeal redness does not start to shoal.
Statistical method: adopt SPSS12.0 statistics software to carry out statistical procedures, compare between metering and enumeration data group and adopt t inspection and x
2inspection, with p<0.05 for there being statistical significance difference.
Result:
Table 4 the 4th day each group patients symptomatic improves situation and compares
Each experimental group group compares above, P>0.05, indifference.
Table 5 is respectively organized patient sign improvement situation on the 4th day and is compared
Each experimental group group compares above, P>0.05, indifference.
Conclusion: use experiment through human body, result shows that the low sugar syrup of use 6%, 8%, 10%, 12% biological activity hyaluronic acid and 30%, 40%, 50% Sorbitol manufacture all has therapeutic effect to laryngopharyngitis.Use is less than 30% and starts unrealistic (namely can not realize paste very little, lack flowable too much), not at this experiment authentication area with being greater than 50% Sorbitol manufacture low sugar syrup production and using.
Embodiment 6
Biological activity hyaluronic acid low sugar syrup
Formula: biological activity hyaluronic acid 6-12%, Sorbitol 30-50%, white sugar 0.1-1%, brown sugar 0.5-2%, maltose alcohol 0.5-6.7%, Mint Essence 0.001-0.01%, Mel 0.1-1%, sodium benzoate 0.1-0.3%, surplus is water.
Embodiment 7
Biological activity hyaluronic acid low sugar syrup food description
Specification: 20ml/ props up
Main component: biological activity hyaluronic acid, sugar, Sorbitol, antiseptic, essence, water.
Effect: form mouth, pharynx, esophagus hyaluronic acid protective layer, supplements hyaluronic acid in mouth, pharynx, esophageal mucosa membrane injury and body.
Using method: get 3-5 milliliter entrance buccal.
Storage method: airtight room temperature is preserved.
Shelf-life: 2 years.
Embodiment 8
Biological activity hyaluronic acid low sugar syrup declares medical apparatus and instruments description
Specification: 20ml/ props up
Main component: biological activity hyaluronic acid, sugar, Sorbitol, antiseptic, essence, water.
Effect: form mouth, pharynx, esophagus hyaluronic acid protective layer, supplements hyaluronic acid, adjuvant therapy of pharyngitis and cough in mouth, pharynx, esophageal mucosa membrane injury and body.
Using method: get 3-5 milliliter entrance buccal.
Storage method: airtight room temperature is preserved.
Shelf-life: 2 years.
Embodiment 9
Biological activity hyaluronic acid low sugar syrup declares nonprescription drugs description
Specification: 20ml/ props up
Main component: biological activity hyaluronic acid, sugar, Sorbitol, antiseptic, essence, water.
Effect: antiinflammatory and the secretion of promotion defensin 2, treatment pharyngitis and cough.
Using method: get 3-5 milliliter entrance buccal.
Storage method: airtight room temperature is preserved.
Shelf-life: 2 years.
The above; it is only preferred embodiment of the present invention; not do any pro forma restriction to the present invention, those skilled in the art utilize the technology contents of above-mentioned announcement to make a little simple modification, equivalent variations or modification, all drop in protection scope of the present invention.
Claims (7)
1. a biological activity hyaluronic acid syrup preparation, is characterized in that, comprises the biological activity hyaluronic acid with anti-inflammatory activity, has the synergistic Sorbitol of potentiation with described biological activity hyaluronic acid.
2. biological activity hyaluronic acid syrup preparation according to claim 1, is characterized in that, described in there is anti-inflammatory activity the biological activity hyaluronic acid fragments of biological activity hyaluronic acid to be molecular weight be 0.7KD-100KD.
3. biological activity hyaluronic acid syrup preparation according to claim 2, it is characterized in that, described biological activity hyaluronic acid fragments is that the recombined human hyaluronidase PH20 of saccharifying that has using Chinese hamster ovary celI to produce cuts the acquisition of macromole hyaluronic acid, and described hyaluronic acid fragments has at least one end to be the end using the recombined human hyaluronidase cutting that can identify hyaluronic acid normal configuration.
4. biological activity hyaluronic acid syrup preparation according to claim 1, it is characterized in that, described syrup preparation is low sugar syrup preparation, comprise the following component of percentage by weight: described biological activity hyaluronic acid 6-12%, Sorbitol 30-50%, white sugar 0.1-1%, brown sugar 0.5-2%, maltose alcohol 0.5-6.7%, Mel 0.1-1%, sodium benzoate 0.1-0.3%, Mint Essence 0.001-0.01%, surplus is water.
5. biological activity hyaluronic acid syrup preparation according to claim 4, it is characterized in that, described low sugar syrup preparation comprises the following component of percentage by weight: described biological activity hyaluronic acid 10%, Sorbitol 40%, white sugar 1%, brown sugar 2%, maltose alcohol 6.7%, Mel 1%, sodium benzoate 0.3%, Mint Essence 0.01%, and surplus is water.
6. biological activity hyaluronic acid syrup preparation according to claim 1, it is characterized in that, described syrup preparation is high sugared syrup preparation, comprise the following component of percentage by weight: described biological activity hyaluronic acid 6-12%, Sorbitol 1-3%, maltose 30-35%, sucrose 10-12%, brown sugar 10%, Mel 1-3%, Mint Essence 0.5-1%, surplus is water.
7. biological activity hyaluronic acid syrup preparation according to claim 6, it is characterized in that, the sugared syrup preparation of described height comprises the following component of percentage by weight: described biological activity hyaluronic acid 10%, Sorbitol 2%, maltose 30%, sucrose 10%, brown sugar 10%, Mel 3%, Mint Essence 1%, and surplus is water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510065498.4A CN104548106A (en) | 2015-02-09 | 2015-02-09 | Bioactive hyaluronic acid syrup preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510065498.4A CN104548106A (en) | 2015-02-09 | 2015-02-09 | Bioactive hyaluronic acid syrup preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104548106A true CN104548106A (en) | 2015-04-29 |
Family
ID=53065871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510065498.4A Pending CN104548106A (en) | 2015-02-09 | 2015-02-09 | Bioactive hyaluronic acid syrup preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104548106A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106309471A (en) * | 2015-07-02 | 2017-01-11 | 惠觅宙 | Applications and preparation of low-molecular-weight biological active hyaluronic acid |
| CN107303271A (en) * | 2016-04-25 | 2017-10-31 | 惠觅宙 | A kind of parenteral solution containing micromolecule hyaluronic acid and application thereof |
| US11576925B2 (en) | 2016-04-25 | 2023-02-14 | Mizhou Hui | Application of low-molecular-weight hyaluronic acid (LMW-HA) fragments |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1939336A (en) * | 2005-09-26 | 2007-04-04 | 株式会社糖质科学研究所 | Pharmaceutical agent containing hyaluronan as an active ingredient |
| CN103468662A (en) * | 2013-09-29 | 2013-12-25 | 惠觅宙 | Recombined human hyaluronidase, production and purification method and preparations thereof, use method and application |
-
2015
- 2015-02-09 CN CN201510065498.4A patent/CN104548106A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1939336A (en) * | 2005-09-26 | 2007-04-04 | 株式会社糖质科学研究所 | Pharmaceutical agent containing hyaluronan as an active ingredient |
| CN103468662A (en) * | 2013-09-29 | 2013-12-25 | 惠觅宙 | Recombined human hyaluronidase, production and purification method and preparations thereof, use method and application |
Non-Patent Citations (2)
| Title |
|---|
| 惠觅宙等: "小分子透明质酸在老年皮肤粘膜保健及炎症防御中的应用", 《皮肤性病诊疗学杂志》 * |
| 赵含丹等: "生物活性透明质酸片段治疗慢性咽炎初步探讨", 《临床军医杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106309471A (en) * | 2015-07-02 | 2017-01-11 | 惠觅宙 | Applications and preparation of low-molecular-weight biological active hyaluronic acid |
| CN107303271A (en) * | 2016-04-25 | 2017-10-31 | 惠觅宙 | A kind of parenteral solution containing micromolecule hyaluronic acid and application thereof |
| US11576925B2 (en) | 2016-04-25 | 2023-02-14 | Mizhou Hui | Application of low-molecular-weight hyaluronic acid (LMW-HA) fragments |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2325043T3 (en) | INULINE DIETETIC FIBER ADMINISTRATION SYSTEM. | |
| US20040029774A1 (en) | Composition and methods for the treatment of musculoskeletal disorders and collagen and elastin deficiencies | |
| EP1976562B1 (en) | Water-soluble films comprising low-viscosity alginates | |
| CA2676058C (en) | Diet product comprising alginate | |
| CA2337152C (en) | Pharmaceutical composition intended in particular for the prevention and the treatment of radiomucositis and chemomucositis | |
| TW200942228A (en) | Oral or enteral composition useful for recovery of physical functions | |
| WO2005094782A1 (en) | Delivery systems for antacids | |
| PT1841332E (en) | Thickener composition for dysphagia patients | |
| CN104546896A (en) | Bioactive hyaluronic acid gel preparation | |
| US20070134280A1 (en) | Thixotropic ingestible formulation to treat sore throat | |
| CN104548106A (en) | Bioactive hyaluronic acid syrup preparation | |
| WO2004080470A1 (en) | Preventive/remedy for obesity | |
| JP5079713B2 (en) | Gastric raft composition comprising preferably processed starch for inducing satiety | |
| EP3773615B1 (en) | Liquid composition for use in the treatment of the mucosa of the oro-pharyngo-laryngo-esophageal tract | |
| US20070292517A1 (en) | Delivery Systems for Antacids | |
| JP3199097U (en) | Tablets containing black vinegar glucosamine mixture | |
| EP1788000A1 (en) | Agent for preventing and ameliorating obesity | |
| US20050070500A1 (en) | Method of modulating release of saccharides and uses thereof | |
| ES2402643B1 (en) | Combination of anti-cholesterolemic fiber | |
| CN112425703A (en) | Oral health improving product containing plant exosomes | |
| JP2022550457A (en) | Methods of treating or preventing obesity and weight management | |
| CN104906131B (en) | A kind of preparation method preventing and treating lamb stomatitis plaster | |
| JP6330119B2 (en) | Beauty composition | |
| CN102247315B (en) | OTC (Over the Counter) drug frozen sucker for treating symptoms of upper respiratory tract and oral cavity and preparation method thereof | |
| KR102512267B1 (en) | Oral film containing a composition including low molecular weight collagen, elastin, hyaluronic acid and boswellia extract as active ingredients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150429 |
|
| RJ01 | Rejection of invention patent application after publication |